Cannabidiol redirects macrophage signaling and eases fibrotic liver injury
Cannabidiol reduced liver injury and fibrotic remodeling in a bile duct ligation model, while also restraining the macrophage polarization program that drives stellate cell activation. The work places TRPV4, RhoA/ROCK, and STAT6 in the same mechanistic chain and suggests that immune-cell reprogramming can blunt the fibrotic cascade before collagen accumulation becomes self-sustaining.
The study addressed a central problem in hepatic fibrosis: once extracellular matrix builds up and hepatic architecture begins to fail, the liver enters a cycle in which inflammation, immune signaling, and stellate-cell activation reinforce one another. M2-like macrophages are part of that loop. They are often discussed as repair-oriented cells, but in chronic liver injury their profibrotic output helps push stellate cells toward the activated, collagen-producing state that defines progressive fibrosis.
CBD was tested in that context both in vivo and in vitro. In bile duct-ligated mice, CBD treatment eased hepatic damage, reduced inflammatory markers, and improved indicators of liver function. Histology also showed less fibrotic change, with lower collagen deposition and fewer signs of the architectural distortion that typically follows persistent cholestatic injury. The comparison with the untreated BDL group pointed in the same direction across biochemical and tissue-based readouts.
One result stands out clearly: CBD did not act as a simple anti-inflammatory patch. It altered the cellular conversation that sustains fibrosis.
TRPV4 sits upstream of the macrophage-to-stellate cell axis
The mechanistic work centered on TRPV4, a mechanosensitive ion channel linked to fibrotic behavior across several organs. In this study, CBD was positioned as a modulator of TRPV4-linked signaling rather than as a broadly nonspecific inhibitor of inflammation. Computational approaches, including transcriptomic analysis, single-cell transcriptomics, network pharmacology, molecular docking, and dynamic conformational modeling, were used to support the possibility of CBD binding to TRPV4.
Those computational findings were then paired with wet-lab validation. In THP-1-derived macrophages, IL-4 drove M2-like polarization, and CBD suppressed that shift. Expression of M2-associated markers fell, along with pro-fibrotic factors that would normally help activate stellate cells. In parallel, CBD reduced signaling through RhoA/ROCK and influenced STAT6 phosphorylation, two pathways tightly tied to cytoskeletal remodeling and IL-4-driven macrophage programming.
The biological consequence was not limited to the macrophages themselves. Conditioned medium from CBD-treated M2-like macrophages was less able to activate LX-2 stellate cells, and those stellate cells showed reduced expression of Col-I and α-SMA. Their migration and proliferation also dropped. In practical terms, the immune cell that would normally instruct fibrogenesis became a weaker driver of scar formation.
Stellate-cell activation fell as profibrotic macrophage cues weakened
The co-culture experiments are the most clinically intuitive part of the paper because they recreate a common pattern in liver disease: immune cells shift the local environment first, and stromal cells amplify the injury afterward. Here, CBD appears to interrupt that relay. By dampening M2-like polarization, the compound reduced the paracrine signals that ordinarily push hepatic stellate cells into an activated, fibrogenic state.
This is where the TRPV4/RhoA/ROCK axis matters. TRPV4 has been implicated in mechanotransduction, and fibrosis itself stiffens tissue, creating a feed-forward loop. If TRPV4 helps macrophages interpret that changing mechanical environment, then blocking the channel could make the immune compartment less responsive to the cues that sustain fibrosis. The study’s data are consistent with that model, although they remain preclinical and do not prove the same sequence in human disease.
A second punchline emerged from the inhibitor experiments. Co-administering CBD with the TRPV4 inhibitor RN-1734 strengthened the anti-fibrotic effect in both animals and cells. That finding supports the idea that TRPV4 is not merely associated with the response but participates in the pathway CBD is influencing.
Human tissue data aligned with the experimental model
Human liver specimens added a translational layer to the work. Fibrotic tissue and non-fibrotic control samples were examined alongside the experimental systems, and the tissue-level analysis supported the broader concept that macrophage behavior and fibrotic progression move together. The paper does not present a clinical treatment result in patients, but it does anchor the preclinical mechanism in human liver material rather than in a purely artificial cell system.
The study design also deserves attention because it combined several methodological angles. Histopathology, immunohistochemistry, immunofluorescence, flow cytometry, western blotting, qRT-PCR, CETSA, Co-IP, and mass spectrometry all pointed toward the same directional effect: CBD suppressed the macrophage phenotype associated with fibrosis and weakened downstream stellate-cell activation. The convergence across platforms strengthens the internal consistency of the findings.
Still, the work leaves several clinically important gaps. The model is cholestatic and surgically induced, so it does not automatically translate to every fibrosis subtype seen in practice, including metabolic or viral disease. The CBD dosing used in mice cannot be assumed to map cleanly onto human dosing, and the study does not establish long-term safety, oral bioavailability, or clinical efficacy in patients with chronic liver disease.
The most useful takeaway is narrower and more immediate: CBD reduced hepatic fibrosis in this preclinical system by suppressing M2-like macrophage polarization and interfering with TRPV4/RhoA/ROCK signaling. The work points to macrophage reprogramming as a potential therapeutic route in hepatic fibrogenesis, while leaving the real-world question of patient benefit for future clinical testing.